Of relevance, in stable CAD/COPD patients, following ticagrelor treatment we also found decreased serum levels of epidermal growth factor (EGF), increased NO generation in HUVECs treated with patient’s serum, measured by diaminofluorescein (DAF) assay, and attenuated reactive oxygen species (ROS) production in PBMC isolated from patients, assessed by flow cytometric analysis [2,6]. Here, EGF is linked to coronary artery disorder.